Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype.
Bardet V, Costa LD, Elie C, Malinge S, Demur C, Tamburini J, Lefebvre PC, Witz F, Lioure B, Jourdan E, Pigneux A, Ifrah N, Attal M, Dreyfus F, Mayeux P, Lacombe C, Bennaceur-Griscelli A, Bernard OA, Bouscary D, Récher C; GOELAMS: Groupe Ouest Est d'etude des Leucémies et des Autres Maladies du Sang. Bardet V, et al. Among authors: ifrah n. Leukemia. 2006 Sep;20(9):1644-6. doi: 10.1038/sj.leu.2404294. Epub 2006 Jun 22. Leukemia. 2006. PMID: 16791266 No abstract available.
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.
Chevallier P, Fornecker L, Lioure B, Béné MC, Pigneux A, Recher C, Witz B, Fegueux N, Bulabois CE, Daliphard S, Bouscary D, Vey N, Delain M, Bay JO, Turlure P, Bernard M, Himberlin C, Luquet I, Ifrah N, Harousseau JL; GOELAMS. Chevallier P, et al. Among authors: ifrah n. Leukemia. 2010 Jul;24(7):1380-5. doi: 10.1038/leu.2010.111. Epub 2010 May 27. Leukemia. 2010. PMID: 20508614 Clinical Trial. No abstract available.
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Willems L, et al. Among authors: ifrah n. Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6. Leukemia. 2012. PMID: 22143671
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P, Cahn JY, Leguay T, Bories P, Witz F, Lamy T, Mayeux P, Lacombe C, Demur C, Tamburini J, Merlat A, Delepine R, Vey N, Dreyfus F, Béné MC, Ifrah N, Bouscary D; GOELAMS (Groupe Ouest Est d’Etude des Leucémies aiguës et Autres Maladies du Sang). Park S, et al. Among authors: ifrah n. Leukemia. 2013 Jul;27(7):1479-86. doi: 10.1038/leu.2013.17. Epub 2013 Jan 16. Leukemia. 2013. PMID: 23321953 Clinical Trial.
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.
Récher C, Béné MC, Lioure B, Pigneux A, Vey N, Delaunay J, Luquet I, Hunault M, Guyotat D, Bouscary D, Fegueux N, Jourdan E, Lissandre S, Escoffre-Barbe M, Bonmati C, Randriamalala E, Guièze R, Ojeda-Uribe M, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Guardiola P; Groupe Ouest-Est d’ étude des Leucé mies Aiguës et autres. Récher C, et al. Among authors: ifrah n. Leukemia. 2014 Feb;28(2):440-3. doi: 10.1038/leu.2013.290. Epub 2013 Oct 9. Leukemia. 2014. PMID: 24166215 No abstract available.
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Largeaud L, Cornillet-Lefebvre P, Hamel JF, Dumas PY, Prade N, Dufrechou S, Plenecassagnes J, Luquet I, Blanchet O, Banos A, Béné MC, Bernard M, Bertoli S, Bonmati C, Fornecker LM, Guièze R, Haddaoui L, Hunault M, Ianotto JC, Jourdan E, Ojeda M, Peterlin P, Vey N, Zerazhi H, Yosr H, Mineur A, Cahn JY, Ifrah N, Récher C, Pigneux A, Delabesse E; French Innovative Leukemia Organization (FILO). Largeaud L, et al. Among authors: ifrah n. Leukemia. 2021 May;35(5):1291-1300. doi: 10.1038/s41375-020-01031-1. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32943750 Clinical Trial.
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Sadoun A, Ifrah N, Guyotat D, Faucher C, Fegueux N, Reiffers J, Maraninchi D, Blaise D. Mohty M, et al. Among authors: ifrah n. Leukemia. 2003 May;17(5):869-75. doi: 10.1038/sj.leu.2402909. Leukemia. 2003. PMID: 12750699
305 results